KPV — Safety, Research, Risks & Legal Status

Not medical advice. KPV is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Lysine-Pro-Valine, LL-37 fragment
Category	Peptide
LL-37	Full-length 37-amino acid peptide found in human neutrophils, macrophages, and epithelial cells
FPR2	Formyl-peptide receptor 2; also called ALX or FPRL1; G-protein coupled receptor on immune cells
US legal status	Research chemical; not FDA-approved for human use; sold as research only in US

What is KPV?

Tripeptide derived from cathelicidin antimicrobial peptide LL-37; proposed to reduce inflammation and support immune modulation. KPV is a short-chain fragment studied for its ability to stabilize mast cells and modulate pro-inflammatory signaling without the full-length LL-37 effects.

How it works

KPV binds formyl-peptide receptors (FPR2/ALX) on immune cells, triggering signaling cascades that suppress NF-kappa-B activation and reduce pro-inflammatory cytokine release. The peptide modulates macrophage and neutrophil behavior, shifting toward anti-inflammatory phenotypes without systemic immunosuppression.

Background & history

KPV was identified as a bioactive fragment of LL-37 during studies of innate immunity in the early 2000s. Research focused on inflammatory skin and gut conditions. Interest in KPV alone grew as a potential therapeutic with reduced side-effect profile versus full LL-37.

What the research says

Preclinical and early human studies suggest anti-inflammatory effects; most evidence in cell and animal models; limited peer-reviewed human data. Cell culture work shows suppression of TNF-alpha and IL-8; animal models of colitis and wound healing show promising results, but human trials remain sparse and mostly observational.

Reported effects

Reported to reduce pro-inflammatory cytokines in vitro and in animal models
Studied for skin barrier support and mast cell stabilization
May modulate immune response to reduce excessive inflammation
Animal studies suggest potential antimicrobial properties
Proposed to dampen excessive histamine release in inflammatory conditions

Dosing & administration (informational)

Preclinical studies used peptide at micro to nanomolar concentrations in cell culture (0.1-10 micromolar). Animal studies reported topical and injection protocols ranging 1-10 mg/kg, with topical application preferred in skin models. No human dose standards exist; research chemical suppliers vary widely.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Generally well-tolerated in preclinical studies at studied doses
No known major toxicities in animal research; human safety data sparse
Synth quality critical: verify third-party COA; contamination risk if not GMP
Topical use preferred to minimize injection risk; if injected, use only sterile, endotoxin-tested vials
Pregnancy and breastfeeding: insufficient data; avoid
Immune-suppressed individuals should consult before use due to immunomodulatory properties

Drug & supplement interactions

May interact with antihistamines (both may suppress mast cell function); unknown synergy
Potential interaction with TNF-alpha inhibitors; immune overlap unclear
Combination with immunosuppressants not studied; avoid concurrent use
No known interactions with NSAIDs or corticosteroids, but not formally tested

Who should avoid it

Active systemic infection or sepsis (immune function unknown in acute illness)
Severe immunocompromise (HIV, transplant recipients on heavy immunosuppression)
Known mast cell disorders or mastocytosis (already dysregulated)
Pregnancy and nursing (insufficient data)
Injection if source is not verified GMP (bacterial endotoxin and pyrogen risk)

How it is commonly combined

KPV is sometimes combined with other immune-support peptides (such as BPC-157) or topical anti-inflammatory agents (vitamin C serums, niacinamide) in informal protocols, but no clinical validation exists for these combinations.

Legal & regulatory. Research chemical; not FDA-approved for human use; sold as research only in US

Quality & harm reduction

R
e
q
u
i
r
e
t
h
i
r
d
-
p
a
r
t
y
C
O
A
(
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
)
f
r
o
m
a
c
c
r
e
d
i
t
e
d
l
a
b
.
H
P
L
C
a
n
d
/
o
r
L
C
-
M
S
p
u
r
i
t
y
r
e
p
o
r
t
(
a
i
m
f
o
r
9
8
%
+
p
u
r
i
t
y
)
.
E
n
d
o
t
o
x
i
n
t
e
s
t
i
n
g
(
E
U
t
e
s
t
o
r
L
A
L
a
s
s
a
y
)
.
S
t
e
r
i
l
e
,
s
i
n
g
l
e
-
u
s
e
v
i
a
l
s
w
i
t
h
c
l
e
a
n
r
e
c
o
n
s
t
i
t
u
t
i
o
n
p
r
o
c
e
d
u
r
e
;
s
t
o
r
e
c
o
l
d
(
2
-
8
°
C
)
o
r
f
r
e
e
z
e
(
-
2
0
°
C
)
.

Safer, legal alternative we recommend

Omega-3 fatty acids and quality sleep. Both have strong evidence for reducing systemic inflammation and supporting immune modulation without research-chemical risk.

See our recommended pick

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is KPV FDA-approved?

No. It is a research chemical and not approved by the FDA for medical use.

What is the evidence for anti-inflammatory effects?

Most evidence comes from cell and animal studies. Very few published human trials exist; marketed claims often exceed current data.

How do I use it safely?

If obtained for personal research: use only GMP-synthesized material with COA; prefer topical (cream/serum) over injection to reduce infection risk; if injecting, use only sterile, endotoxin-tested single-use vials.

Can I combine KPV with other supplements?

Unknown; no robust interaction studies. Consult a doctor if using prescription medications or immunosuppressants.

Is KPV a peptide?

Yes; it is a tri-peptide (three amino acids: lysine, proline, valine) derived from the larger LL-37 peptide.

References & further reading

LL-37 and antimicrobial peptide biology: comprehensive review in Nature Reviews Immunology
FPR2/ALX receptor signaling: mechanistic studies in Journal of Immunology
Mast cell stabilization and innate immunity: immunology textbooks and review articles
Topical peptide delivery and skin barrier: dermatology and pharmaceutical chemistry literature
KPV preclinical studies: limited primary literature; many studies in non-English or conference proceedings